Spending More or Less, and on What? - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Spending More or Less, and on What?
Pharmaceutical Technology's annual survey on equipment and machinery reveals the spending levels and types of spending made in 2009 and planned for 2010.


Pharmaceutical Technology
Volume 34, Issue 4, pp. 48-56

Innovation


Figure 5
Innovation is an important consideration in purchasing decisions. The survey showed that 16.1% of respondents said that innovation is "extremely important" in their purchasing decisions, and 47.7% said it was "very important." Respondents were fairly favorable in evaluating the level of innovation in equipment and machinery during the past two years (2008 and 2009) (see Figure 5). Almost one-quarter of respondents said that innovation in machinery and equipment for quality assurance and control was "high," and 50.7% ranked the level of innovation as "medium" (see Figure 5).


Figure 6:
Respondents felt innovation was highest in disposables or single-use components for biopharmceutical manufacturing, followed by process control and automation, and analytical instrumentation (See Figure 6). Product areas that showed the lowest levels of innovation according to survey respondents were vial- or syringe-filling and tablet presses or capsule-filling machines. Almost half of the respondents (49%) said there has been "none or low" innovation in equipment for vial- or syringe-filling, and 47.6% said there has been "none or low" innovation for tablet presses or capsule-filling machines during the past two years (see Figure 6).


Respondents profile

QbD and PAT


Figure 7:
Among survey respondents, adoption of PAT was low. Two-thirds of respondents (67.1%) said that their company does not incorporate PAT into its manufacturing processes, and 32.9% of companies said they have incorporated PAT. For those companies that do incorporate PAT, the leading benefit cited by respondents was better process understanding (73% of respondents cited as a benefit) (see Figure 7). Almost half of the respondents using PAT said that it increased efficiency and reduced waste.


Figure 8:
Cost–benefit factors were the leading reasons for companies not incorporating PAT into their manufacturing processes. Almost one-third of respondents (31.8%) said that "benefits do not justify the effort to implement" (see Figure 8). One-quarter of respondents said PAT implementation was too costly, and one-quarter also said that their companies do not use PAT because it would require new equipment or procedures (see Figure 8).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here